Richmond, Va. (June 22, 2012) – A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.
Recently published in the journal Brachytherapy, a novel treatment protocol designed by Michael Hagan, M.D., Ph.D., radiation oncologist at VCU Massey Cancer Center, that combines intensity-modulated radiation therapy with high-dose rate (HDR) brachytherapy was tested on 26 prostate cancer patients. Intensity-modulated radiation therapy uses computer-controlled linear accelerators to modulate the intensity of an external radiation beam to more accurately deliver radiation to tumors. HDR brachytherapy is an internal form of radiation therapy that uses small radioactive pellets implanted near the tumor.
"Recent studies have shown that both higher daily doses and higher total doses of radiation are better than standard doses in controlling prostate cancer, but these higher doses may be associated with higher rates of bladder and bowel complications," says the study's lead author Mitchell Anscher, M.D., Florence and Hyman Meyers Chair of Radiation Oncology and program co-leader of Radiation Biology and Oncology at VCU Massey Cancer Center. "Our study was designed to reduce radiation exposure to nearby healthy tissue and organs and we were pleased to find that this unique dosing schedule is safe and effective."
The toxicity of the therapy was relatively low and all 26 patients were able to complete treatment. The treatment required only one HDR brachytherapy implant, and all participants were treated as outpatients. After 4.5 years, none of the patients relapsed and the rate of long-term side effects was low.
"Our goal is to improve outcomes for our patients, so we are continually researching ways to reduce unnecessary radiation exposure to healthy tissues and make treatments shorter and more manageable. We're hopeful our findings will lead to better tumor control rates and fewer complications for men with prostate cancer," says Anscher.
Moving forward, the researchers plan to continue exploring prostate cancer therapies using higher dose rates and shorter treatment times. The next step will likely be a four-treatment study utilizing stereotactic body radiosurgery, a technique popular with brain cancer that provides higher accuracy and requires fewer treatments by focusing high-powered X-rays on a very small area.
In addition to Hagan, Anscher collaborated on this study with Michael Myers, M.D., Dorin Todor, Ph.D., Lynn Gilbert, Ph.D., Nitai Mukhopadhyay, Ph.D., Jessica Randolph, M.D., and Jeffrey Heilmiller from VCU Massey Cancer Center's Department of Radiation Oncology.
View the full manuscript of this study at: http://www.sciencedirect.com/science/article/pii/S1538472111003564
This study was supported, in part, with funding from VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 66 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 31,000 students in 222 certificate and degree programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.